Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 702Carcinoma, Non-Small-Cell Lung 470Prostatic Neoplasms 419Neoplasms 381Multiple Myeloma 265Colorectal Neoplasms 261Lung Neoplasms 247Neoplasm Metastasis 227Melanoma 215Ovarian Neoplasms 193Leukemia, Myeloid, Acute 189Pancreatic Neoplasms 182Squamous Cell Carcinoma of Head and Neck 162Recurrence 146Carcinoma, Renal Cell 145Lymphoma 142Glioblastoma 138Lymphoma, Non-Hodgkin 135Stomach Neoplasms 128Triple Negative Breast Neoplasms 126Brain Neoplasms 124Leukemia, Lymphocytic, Chronic, B-Cell 123Carcinoma, Hepatocellular 123Uterine Cervical Neoplasms 117Head and Neck Neoplasms 117Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Urinary Bladder Neoplasms 113Lymphoma, Large B-Cell, Diffuse 105Sarcoma 102Lymphoma, Follicular 100

Interventions

Tamoxifen 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Breast Cancer Subjects × Clear all
NCT06449027 2025-10-01

Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
211 enrolled
Breast

Breast Cancer Subjects

Data powered by HemOnc (CC BY 4.0) Colophon âš¡